Emergent BioSolutions Inc. (EBS) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector, currently trading at $8.66. It has a SharesGrow Score of 53/100, indicating a mixed investment profile with 2 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of EBS = $4.16 (-52% from the current price, the stock appears overvalued). Analyst consensus target is EBS = $52 (+494.7% upside).
Valuation: EBS trades at a trailing Price-to-Earnings (P/E) of 8.5 (S&P 500 average ~25).
Financials: revenue is $743M, -12.2%/yr average growth. Net income is $53M, growing at -12.4%/yr. Net profit margin is 7.1% (thin). Gross margin is 47.2% (+9.1 pp trend).
Balance sheet: total debt is $572M against $523M equity (Debt-to-Equity (D/E) ratio 1.09, moderate). Current ratio is 5.01 (strong liquidity). Debt-to-assets is 43.4%. Total assets: $1.3B.
Analyst outlook: 11 / 15 analysts rate EBS as buy (73%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 15/100 (Fail), Past 25/100 (Fail), Health 50/100 (Partial), Moat 51/100 (Partial), Future 85/100 (Pass), Income 45/100 (Partial).
